GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (FRA:26CA) » Definitions » Research & Development

ImmunityBio (FRA:26CA) Research & Development : €171.20 Mil (TTM As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is ImmunityBio Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. ImmunityBio's Research & Development for the three months ended in Mar. 2025 was €44.62 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was €171.20 Mil.

ImmunityBio Research & Development Historical Data

The historical data trend for ImmunityBio's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunityBio Research & Development Chart

ImmunityBio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial 114.68 173.42 234.25 213.08 181.59

ImmunityBio Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.08 47.50 45.45 33.64 44.62

ImmunityBio Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €171.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmunityBio  (FRA:26CA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

ImmunityBio Research & Development Related Terms

Thank you for viewing the detailed overview of ImmunityBio's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmunityBio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (FRA:26CA) » Definitions » Research & Development
Comparable Companies
RXRX DNLI FOLD APLS KYMR ACAD APGE IMVT MLTX LGND VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
IBRX:USA
Address
3530 John Hopkins Court, San Diego, CA, USA, 92121
Website
https://www.immunitybio.com
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

ImmunityBio Headlines

No Headlines